Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study.

Wierzbicki, A S; Pendleton, S; McMahon, Z; Dar, A; Oben, J; Crook, M A; Botha, A J

Wierzbicki, A S; Pendleton, S; McMahon, Z; Dar, A; Oben, J; Crook, M A; Botha, A J.

Int J Clin Pract ; 65(6): 713-5, 2011 Jun.

Article in En | MEDLINE | ID: mdl-21564446

Subject(s)

Cannabinoid Receptor Modulators/antagonists & inhibitors; Cholesterol/metabolism; Fatty Liver/drug therapy; Insulin Resistance/physiology; Obesity, Morbid/drug therapy; Piperidines/therapeutic use; Pyrazoles/therapeutic use; Adult; Biomarkers/metabolism; Female; Humans; Hypercholesterolemia/drug therapy; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity, Morbid/metabolism; Retrospective Studies; Rimonabant; Safety-Based Drug Withdrawals; Triglycerides/metabolism; Weight Loss/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperidines / Pyrazoles / Obesity, Morbid / Insulin Resistance / Cholesterol / Fatty Liver / Cannabinoid Receptor Modulators Type of study: Etiology_studies / Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google